Procter & Gamble said net sales for the quarter ended December 31, 2024 increased 2% to $21.9 billion, with unit volume and mix each increasing 1%. Pricing and foreign exchange had a neutral impact on net sales. Excluding the impacts of acquisitions and divestitures and foreign exchange, organic sales increased 3% and organic volume increased 2%.

1. 01

   Procter & Gamble said net sales for the quarter ended December 31, 2024 increased 2% to $21.9 billion, with unit volume and mix each increasing 1%. Pricing and foreign exchange had a neutral impact on net sales. Excluding the impacts of acquisitions and divestitures and foreign exchange, organic sales increased 3% and organic volume increased 2%.

2. 02

   The company said net earnings for the 6 months ended December 31, 2024 were $8.6 billion, an increase of $597 million or 7%, versus the prior year period. It added that the prior year included a non-cash impairment charge on the Gillette intangible asset of $1.3 billion ($1.0 billion after tax), while the current year had higher restructuring charges of $0.8 billion after tax. Diluted EPS increased 8% to $3.49.

3. 03

   Procter & Gamble said operating cash flow for the 6 months ended December 31, 2024 was $9.1 billion, a decrease of $877 million versus the prior year period. Adjusted free cash flow was $7.8 billion, adjusted free cash flow productivity was 83%, and working capital and other factors used $2.2 billion of cash.

4. 04

   The company said it completed a limited market portfolio restructuring with the substantial liquidation of operations in Argentina during the period ended September 30, 2024 and recorded incremental restructuring charges of approximately $0.8 billion after tax. The total incremental restructuring charges incurred under the program since its inception were approximately $1.2 billion after tax.

Key figures

Quarter ended December 31, 2024

Revenue

$21.9B

Operating income

$5.7B

Net income

$4.6B

EPS

$1.88

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.